Persistence of AMGEVITA® in patients with plaque psoriasis: a retrospective database analysis from the British Association of Dermatology Biologics and Immunomodulators Register (20210149)

Study identification

• EU PAS number:
  EUPAS46292
• Study ID:
  47125
• Official title and acronym:
  Persistence of AMGEVITA® in patients with plaque psoriasis: a retrospective database analysis from the British Association of Dermatology Biologics and Immunomodulators Register (20210149)
• DARWIN EU® study:
  No
• Study countries:
  Ireland

  United Kingdom
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Multiple centres: 164 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual: 14/12/2018

Study start date

Actual: 14/12/2018

Data analysis start date

Actual: 14/01/2022

Date of final study report

Planned: 31/12/2022

Actual: 02/05/2023

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable